| Literature DB >> 25721088 |
Zhenyu Xiao1, Haniee Chung1, Babak Banan1, Pamela T Manning2, Katherine C Ott1, Shin Lin3, Benjamin J Capoccia1, Vijay Subramanian1, Ronald R Hiebsch2, Gundumi A Upadhya1, Thalachallour Mohanakumar4, William A Frazier5, Yiing Lin6, William C Chapman7.
Abstract
Human hepatocellular carcinoma (HCC) has a high rate of tumor recurrence and metastasis, resulting in shortened survival times. The efficacy of current systemic therapies for HCC is limited. In this study, we used xenograft tumor models to investigate the use of antibodies that block CD47 and inhibit HCC tumor growth. Immunostaining of tumor tissue and HCC cell lines demonstrated CD47 over-expression in HCC as compared to normal hepatocytes. Macrophage phagocytosis of HCC cells was increased after treatment with CD47 antibodies (CD47mAbs) that block CD47 binding to SIRPα. Further, CD47 blockade inhibited tumor growth in both heterotopic and orthotopic models of HCC, and promoted the migration of macrophages into the tumor mass. Our results demonstrate that targeting CD47 by specific antibodies has potential immunotherapeutic efficacy in human HCC.Entities:
Keywords: Antibody therapy; CD47; HCC; Xenograft models
Mesh：
Substances：
Year: 2015 PMID： 25721088 PMCID： PMC4886734 DOI： 10.1016/j.canlet.2015.02.036
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679